Is melatonin addictive? What the evidence shows
Futures Nutrition Editorial Team · 11 August 2026
Is melatonin addictive? What the evidence shows
11 August 2026
Anyone taking melatonin in the evening for weeks eventually arrives at the question: does the body get used to it? The short answer, by current knowledge, is this: there is no evidence of physical dependence, and none of tolerance either — that is, of the same amount achieving less over time. What does exist is something else: a habituation to the routine. And there is a gap in the data that is fairer to talk about than to skip over — the long-term investigations come almost entirely from the medicines field, not from the supplement shelf.
Melatonin contributes to the reduction of time taken to fall asleep. The beneficial effect is obtained with the consumption of 1 mg of melatonin close to bedtime.
Three terms that constantly get mixed up
A large part of the confusion arises because three different things are called "habituation" in the same discussion. They have different causes and are also studied differently.
| Term | What is meant | How you would notice it |
|---|---|---|
| Tolerance | The same amount achieves less over time | After months you would need more milligrams for the same effect |
| Physical dependence | The body adjusts to the intake | Stopping brings on physical withdrawal symptoms |
| Rebound | After stopping, things are briefly worse than before | The first one or two nights without are more restless than before the first tablet |
There is also a fourth point, which carries no technical name and is nevertheless the most common: the psychological habituation to an evening ritual. More on that below, because it explains most user reports better than anything else.
What the long-term studies show on tolerance
The most meaningful data comes from prolonged-release melatonin (2 mg), authorised in Europe as a prescription-only medicine. That is a different dosage form from an ordinary tablet, but it is the same substance — and it is the only melatonin application that has been studied systematically over months with a discontinuation phase.
| Study | Design | Result on habituation |
|---|---|---|
| Lemoine et al. 2011 | 244 adults, 2 mg prolonged release, 6–12 months, followed by a 2-week discontinuation phase | No sign of tolerance; after stopping, neither rebound nor withdrawal symptoms |
| Wade et al. 2010 | 722 patients analysed, 2 mg prolonged release, 6 months, with a run-down phase | No withdrawal or rebound effects after long-term use |
| Post-authorisation observational study | 597 people surveyed after stopping | Rebound in 3.2 % after 1–2 days, in 2.0 % after two weeks |
The Lemoine study is the most interesting of the three because it measured exactly what is at issue here: withdrawal symptoms were recorded with a dedicated questionnaire, and night-time melatonin excretion in urine was determined. The authors' result: even after twelve months, stopping was associated with neither adverse events nor withdrawal symptoms nor a suppression of the body's own melatonin production.
The third row of the table is the most honest one. Rebound is not at zero — a small share of users report it. But the order of magnitude is a few per cent and one to two nights, not weeks.
Why melatonin behaves differently from sedatives
The suspicion of dependence does not come out of nowhere. It comes from experience with benzodiazepines and the so-called Z-drugs, where tolerance and withdrawal are known problems. The comparison breaks down at the decisive point, however: those substances act at the GABA-A receptor, that is, directly on the damping of the nerve cell. Melatonin does not. It binds to the melatonin receptors MT1 and MT2, which sit above all in the internal clock — it shifts a signal for the time of day instead of pulling a brake.
That is no free pass, but it explains why the side-effect and discontinuation profile differs so clearly. The summary of product characteristics for the authorised melatonin medicine states that sleep measures returned gradually to baseline values after the end of treatment — with no rebound phenomenon, no increase in adverse reactions, no increase in discontinuation symptoms. Stepwise tapering is not provided for there.
Does the body produce less when you supply it from outside?
That is the second major concern, and it sounds plausible: if something arrives from outside, the pineal gland might throttle its own production. It is not documented. In the twelve-month study mentioned above, the body's own production was followed via the urine marker and remained unchanged. Smaller studies with 0.5 mg daily also found no change.
Even so, the point should not be oversold: the number of studies that have measured this directly is small, and they do not cover every dosage. For the amounts that matter here, the available evidence argues against throttling — more than that cannot be made of it.
The habituation that does exist
What many describe as dependence is a learned pattern. Falling asleep depends heavily on expectation and ritual: anyone who takes a tablet for weeks and then falls asleep links the two. When the tablet is dropped, what is missing is not the substance but the building block in the sequence — and the first night without becomes a test you set yourself. That feels real, and it is. It is simply not a physical dependence, and it is handled differently: those who keep the rest of the evening routine and deliberately keep expectations low usually lose that link within a few nights.
When the usual amount no longer seems to be enough
The usual reflex at this point is to increase the strength. Before doing so, it is worth looking at what the authorised claim is actually tied to: 1 mg per portion, close to bedtime. It does not become stronger with more milligrams — there is simply no second authorised claim that would only apply from 5 or 10 mg. Topping up buys more milligrams, not more claim.
More common than a genuine loss of effect, incidentally, is a shifted timing: melatonin is time-critical, and the same amount taken two hours later behaves differently. The authorised claim refers to intake close to bedtime — that is the reference point worth checking before the next strength up.
The four strengths from our range, in ascending order:
Anyone who wants to land on exactly the 1 mg of the authorised claim without keeping two packs takes a tablet with a score line: with the melatonin 2 mg, divisible, half a tablet matches the condition. What else distinguishes the individual strengths is set out in detail in Melatonin dosage: 0.5, 1, 2, 5 or 10 mg?.
For how long at a stretch?
There is no fixed upper limit on the duration of use for food supplements. Two points of orientation exist nonetheless.
The authorised melatonin medicine is intended for short-term use; there, the dosage may be maintained for up to 13 weeks. That is not a safety limit in the sense of "after that it becomes dangerous", but the period for which the authorisation has data.
The German Federal Institute for Risk Assessment advises in its opinion No 42/2024 against taking melatonin-containing food supplements uncritically and in particular over a longer period — the reason is expressly not a demonstrated harm, but the absence of robust long-term data for this product group. As possible undesirable effects the institute names, among others, daytime sleepiness, reduced attention, prolonged reaction times and headache. It also advises against use on one's own initiative by pregnant and breastfeeding women, children and adolescents, and people with certain pre-existing conditions; anyone taking medicines regularly is well advised to settle the question with a doctor.
Food supplements are not a substitute for a balanced and varied diet and a healthy lifestyle.
Stopping: what to expect
From the discontinuation phases of the long-term studies it can be inferred that stepwise reduction is not necessary. Anyone who wants to stop can stop. Two things are realistic to plan for:
- The first one or two nights may be more restless. In the observational study this affected a good three per cent; after two weeks it was still the case for two per cent. By that order of magnitude it is a dip, not a relapse.
- The baseline comes back, not something worse. If falling asleep was difficult before, it is difficult again afterwards — that is not withdrawal, it is the state without. That distinction is the actual core of the question.
Anyone still weighing up whether it should be melatonin at all will find the distinction from plant-based alternatives in Melatonin, valerian and ashwagandha compared. And how long a single portion carries on at all is covered in Melatonin duration.
The short version
- Tolerance: not detectable in studies over 6 to 12 months.
- Physical dependence: no evidence, not even after twelve months.
- Rebound: in a few per cent, for one to two nights.
- Own production: not suppressed in the available measurements.
- The real habituation is the one to the ritual — and that concerns the mind, not the receptor.
- Even so, for food supplements: long-term data is missing, and the BfR advises against uncritical continuous use.
Frequently asked questions
Do I have to increase the amount over time?
It does not look that way. In the twelve-month study with 2 mg there was no sign of tolerance. If the impression arises that it no longer carries, it is worth looking first at the time of intake and the rest of the evening — not at the next strength up.
Can I simply stop melatonin or do I need to taper?
Based on the available discontinuation phases, tapering is not required; the summary of product characteristics for the authorised medicine likewise does not provide for one. A small share of users report one to two more restless nights.
Are there withdrawal symptoms?
None were found in the long-term studies using standardised questionnaires. A single case report describes symptoms after stopping in a patient with severe brain damage — that is an exceptional constellation and cannot be generalised.
Then why does the BfR warn against longer use?
Because "no evidence of harm" is not the same as "proven harmless". For food supplements containing melatonin, long-term data across the board is lacking, and part of the amounts sold lies well above what has been studied. The recommendation is directed against open-ended continuous use without cause, not against use as such.
Matching products from our range
- Melatonin 0.5 mg – 365 tablets
- Melatonin 2 mg, divisible to 1 mg – 180 tablets
- View all melatonin products
Sources: Regulation (EU) No 432/2012 (authorised health claims, melatonin: 1 mg close to bedtime); Lemoine P. et al., "Prolonged-release melatonin for insomnia – an open-label long-term study of efficacy, safety, and withdrawal", Therapeutics and Clinical Risk Management 2011, 7:301–311; Wade A.G. et al., "Nightly treatment of primary insomnia with prolonged release melatonin for 6 months", BMC Medicine 2010; German Federal Institute for Risk Assessment (BfR), opinion No 42/2024 "Melatonin-containing food supplements: BfR points out possible health risks"; summary of product characteristics, Circadin 2 mg prolonged-release tablets (sections on dosage and clinical efficacy); review article "Current Insights into the Risks of Using Melatonin as a Treatment for Sleep Disorders in Older Adults", Clinical Interventions in Aging 2022.
